Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial autophagy and metabolic regulation modules represent a complex network of interconnected biological processes that maintain cellular energy balance and organelle quality (Vara-Perez et al., 2019, Frontiers in Oncology). Mitophagy, the selective degradation of damaged or redundant mitochondria via the autophagic pathway, is tightly coupled with metabolic shifts such as the transition between oxidative phosphorylation and glycolysis. This coordination is primarily governed by master regulators like AMPK and mTOR, which sense nutrient availability and cellular stress to adjust mitochondrial turnover and metabolic output (Hardie et al., 2012, Nature Reviews Molecular Cell Biology). Dysregulation of these modules is a hallmark of various pathologies, including cancer, where metabolic reprogramming supports rapid proliferation, and neurodegenerative diseases, where the accumulation of dysfunctional mitochondria leads to neuronal death (Youle & Narendra, 2011, Nature Reviews Molecular Cell Biology). Therapeutic strategies targeting these modules, such as the use of Urolithin A or Metformin, aim to restore mitochondrial health or exploit metabolic vulnerabilities, though the complexity of these pathways presents challenges in achieving tissue-specific effects without disrupting systemic homeostasis (D'Amico et al., 2021, Trends in Molecular Medicine).
Drugs targeting these modules typically act by modulating key signaling nodes such as AMPK (adenosine monophosphate-activated protein kinase) to stimulate mitophagy or mTOR (mammalian target of rapamycin) to regulate protein synthesis and autophagy (Hardie et al., 2012, Nature Reviews Molecular Cell Biology). Other agents may directly induce mitochondrial stress or stabilize mitophagy-related proteins like PINK1 and Parkin to enhance the clearance of damaged mitochondria and shift metabolic flux (Youle & Narendra, 2011, Nature Reviews Molecular Cell Biology).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial autophagy and metabolic regulation modules.